EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Michael King has reiterated a 'Buy' rating on Lantern Pharma (NASDAQ:LTRN) and maintained an $11 price target.
August 10, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst has reiterated a 'Buy' rating on Lantern Pharma and maintained an $11 price target.
The reiteration of a 'Buy' rating by a reputable analyst like Michael King from EF Hutton is a positive signal for Lantern Pharma. The maintained price target of $11 also indicates a positive outlook for the stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100